Concert Pharmaceuticals Q3 EPS $(0.72) Beats $(0.83) Estimate, Sales $10K May Not Compare To $60K Estimate

Concert Pharmaceuticals (NASDAQ:CNCE) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.83) by 13.25 percent. This is a 2.7 percent increase over losses of $(0.74) per share

Benzinga · 11/07/2019 13:26

Concert Pharmaceuticals (NASDAQ:CNCE) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.83) by 13.25 percent. This is a 2.7 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $10 thousand which missed the analyst consensus estimate of $60 thousand by 83.33 percent. This is a 9.09 percent decrease over sales of $11 thousand the same period last year.